GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axsome Therapeutics Inc (NAS:AXSM) » Definitions » Shiller PE Ratio

Axsome Therapeutics (Axsome Therapeutics) Shiller PE Ratio : (As of Apr. 30, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Axsome Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Axsome Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Axsome Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axsome Therapeutics Shiller PE Ratio Chart

Axsome Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Axsome Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Axsome Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Axsome Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Axsome Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Axsome Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Axsome Therapeutics's Shiller PE Ratio falls into.



Axsome Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Axsome Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Axsome Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-2.08/129.4194*129.4194
=-2.080

Current CPI (Dec. 2023) = 129.4194.

Axsome Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 0.000 98.326 0.000
201406 0.000 100.560 0.000
201409 -0.020 100.428 -0.026
201412 -0.117 99.070 -0.153
201503 -0.168 99.621 -0.218
201506 -0.167 100.684 -0.215
201509 -0.258 100.392 -0.333
201512 -0.120 99.792 -0.156
201603 -0.310 100.470 -0.399
201606 -0.360 101.688 -0.458
201609 -0.380 101.861 -0.483
201612 -0.380 101.863 -0.483
201703 -0.410 102.862 -0.516
201706 -0.300 103.349 -0.376
201709 -0.270 104.136 -0.336
201712 -0.310 104.011 -0.386
201803 -0.190 105.290 -0.234
201806 -0.320 106.317 -0.390
201809 -0.310 106.507 -0.377
201812 -0.320 105.998 -0.391
201903 -0.320 107.251 -0.386
201906 -0.410 108.070 -0.491
201909 -0.560 108.329 -0.669
201912 -0.710 108.420 -0.848
202003 -0.880 108.902 -1.046
202006 -0.490 108.767 -0.583
202009 -0.610 109.815 -0.719
202012 -0.780 109.897 -0.919
202103 -0.780 111.754 -0.903
202106 -0.860 114.631 -0.971
202109 -0.930 115.734 -1.040
202112 -0.900 117.630 -0.990
202203 -1.030 121.301 -1.099
202206 -1.060 125.017 -1.097
202209 -1.070 125.227 -1.106
202212 -1.410 125.222 -1.457
202303 -0.260 127.348 -0.264
202306 -1.540 128.729 -1.548
202309 -1.320 129.860 -1.316
202312 -2.080 129.419 -2.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Axsome Therapeutics  (NAS:AXSM) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Axsome Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Axsome Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Axsome Therapeutics (Axsome Therapeutics) Business Description

Traded in Other Exchanges
Address
22 Cortlandt Street, 16th Floor, New York, NY, USA, 10007
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14.
Executives
Susan Mahony director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Mark Coleman director 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Hunter R. Murdock officer: General Counsel 22 CORTLAND STREET, 16TH FLOOR, NEW YORK NY 10007
Roger Jeffs director
Nick Pizzie officer: Chief Financial Officer 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Mark E Saad director C/O CYTORI THERAPEUTICS, INC., 3020 CALLAN ROAD, SAN DIEGO CA 92121
Herriot Tabuteau director, 10 percent owner, officer: CHIEF EXECUTIVE OFFICER
Mark L. Jacobson officer: Chief Operating Officer 200 BROADWAY, 3RD FLOOR, NEW YORK NY 10038
David C Marek officer: Chief Commercial Officer C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011
John Golubieski officer: Chief Financial Officer C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Myrtle S Potter director 10 FINDERNE AVE, BRIDGEWATER NJ 08807
Randall Kaye officer: Chief Medical Officer 11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Ames Constance officer: Vice President, Finance 25 BROADWAY, 9TH FLOOR, NEW YORK NY 10004
Antecip Capital Llc 10 percent owner 630 5TH AVENUE, SUITE 2074, NEW YORK NY 10111